The University of Texas MD Anderson Cancer Center is currently conducting a Phase 1 clinical trial (NCT05621668) to assess the safety and optimal dosage of its innovative attIL12-T cell therapy in patients with advanced soft tissue sarcoma and bone sarcoma, which are difficult-to-treat solid tumors. The trial has garnered significant attention within the industry, as conventional immune cell therapies have faced limitations in overcoming the immunosuppressive tumor microenvironment (TME) of solid tumors. The research team has adopted a unique approach by conjugating interleukin-12 (IL-12) to the cell membrane, as systemic administration of IL-12 is known to cause severe toxicity. This strategy aims to induce localized immune activation specifically within the vicinity of cancer cells, thereby ensuring a safe therapeutic window.

The key innovation of this therapy lies in the fusion of a peptide that targets cell-surface vimentin (CSV) with membrane-bound IL-12 technology. Vimentin, an intracellular cytoskeletal protein, is specifically expressed on the surface of highly metastatic sarcoma cells, making it an effective biomarker. When engineered T cells recognize CSV and reach the tumor tissue, the attached IL-12 stimulates surrounding immune cells, maximizing the anti-cancer effect. This approach offers a promising solution to the persistent challenges associated with IL-12, such as cytokine release syndrome (CRS) and hepatotoxicity, which have previously hindered its clinical development.

The soft tissue and bone sarcoma market represents a substantial opportunity, with an annual value exceeding USD 3 billion across the seven major countries (7MM). However, the five-year survival rate for patients with metastatic disease remains extremely low, underscoring the urgent need for new therapies. Existing standard-of-care treatments, such as doxorubicin and cyclophosphamide, have shown limited efficacy in recurrent patients. Recently, Adaptimmune's TECELRA (afamitresgene autoleucel) received FDA accelerated approval for the treatment of synovial sarcoma, paving the way for the commercialization of cell therapies in solid tumors. Therefore, the attIL12-T cell therapy, with its unique tumor-targeting capabilities, holds significant potential to become a next-generation blockbuster drug.

The clinical trial commenced in September 2023 and is scheduled for completion in September 2027, with patient enrollment and initial data collection currently underway. Although the trial is in its early stages, focusing on safety assessment in a small cohort of patients, the research team led by Professor John Livingston plans to include an expansion cohort of 10 patients with bone sarcoma to comprehensively evaluate preliminary efficacy. If the Phase 1 trial demonstrates the expected levels of safety and efficacy, it is anticipated that early technology licensing or the establishment of a co-development partnership with a major pharmaceutical company will gain momentum. This could represent a significant milestone in providing new treatment options for pediatric and adolescent patients, who are disproportionately affected by bone sarcoma.